LL-37

Investigated uses

• No adequately documented human investigated use for the exact catalog identity/formulation was identified; any vendor-promoted goals were excluded from evidence grading.

Mechanism and hypotheses

• LL-37 is a human cathelicidin antimicrobial peptide with broad innate-immune and membrane-active properties.
• Hypothesized: Therapeutic infection, wound or immune-modulation uses remain investigational and route-specific.

Human evidence

• No qualifying controlled human efficacy study for the exact catalog identity/formulation was identified in this review. Limitations: This is a bounded search conclusion, not proof that no report exists; identity, language and indexing limitations may apply.

Safety highlights

• Unknown or insufficiently characterized for the exact catalog product.
• Identity, purity, sterility, endotoxin, aggregation, immunogenicity, concentration and route-specific risks are not adequately characterized.

Regulatory context

No FDA-approved LL-37 drug was identified; FDA lists LL-37 among substances presenting significant compounding safety concerns.